OTIC Otonomy

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Otonomy, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Otonomy, Inc. (“Otonomy” or the “Company”) (NASDAQ: OTIC) concerning possible violations of federal securities laws.

On August 30, 2017, Otonomy announced that its Phase 3 clinical trial of OTIVIDEX missed its primary endpoint. The Company also announced an immediate suspension of all development activities for OTIVIDEX. David A. Weber, President and CEO of Otonomy, said “We are greatly disappointed by these results, and surprised by both the higher placebo response and lower OTIVIDEX improvement than observed in our previous trials.” Following this news, shares of Otonomy were down more than 80% on intraday trading on August 30, 2017. To obtain additional information, go to:

http://www.zlkdocs.com/OTIC-Info-Request-Form-6068

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
30/08/2017

Underlying

OTICOtonomy

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Otonomy

 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Announces Change in Stock Exchange Listing

Otonomy Announces Change in Stock Exchange Listing SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company’s shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications ...

December 22, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Provides Corporate Update

Otonomy Provides Corporate Update SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of...

December 19, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corp...

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update Evaluation of strategic options to realize value from pipeline is ongoing SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no c...

November 10, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Dos...

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response relationship that has been observed with neurotrophinsOtonomy intends to explore strategic options to advance and realize value from its pipeline including both OTO-413 and OTO-825 SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical c...

October 13, 2022 1 EN
 PRESS RELEASE
Free
OTIC OTONOMY

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Pati...

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022 SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical com...

August 1, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch